Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + cetuximab + capecitabine for metastatic pancreatic cancer
NL-OMON32581Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus, cetuximab and capecitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Planned start Jan 2009; status: not yet recruiting.
02
Drugs
everolimuscetuximabcapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON32581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32581.